// App-Quantinova.ai

: Engineered Bcor Mutations Lead to Acute Lymphoblastic Leukemia of Progenitor B-1 Lymphocyte Origin in a Sensitized Background

Researchers

Presenter

  • Mianmian Yin

Principal Investigators

  • Yang Jo Chung

  • R. Coleman Lindsley

  • Yeulin Zhu

  • Robert L. Walker

  • Benjamin L. Ebert

  • Paul S. Meltzer

  • Peter D. Aplan

Medical Centers

  • CCR, NIH, Bethesda, MD

  • Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • B-cell lymphoma 6

  • Janus kinase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Tasocitinib

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved